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Summary Retinoids and vitamin D are important factors that regulate cellular growth and differentiation. An
additive growth-inhibitory effect of retinoids and vitamin D analogues has been demonstrated for human
myeloma, leukaemic and breast cancer cells. We set out to study the effects of the vitamin D analogue EB1089
and the retinoids all-trans- and 9-cis-retinoic acid on the human pancreatic adenocarcinoma cell lines Capan 1
and Capan 2 and the undifferentiated pancreatic carcinoma cell line Hs766T. The cell lines investigated
expressed vitamin D receptor, retinoic acid receptor (RAR)-a and y as determined by polymerase chain
reaction after reverse transcription. RAR-f, was expressed only in Hs766T cells. Addition of all-trans-retinoic
acid increased the amount of RAR-a mRNA in the three cell lines and induced RAR-,B mRNA in Capan 1 and
Capan 2 cells. All-trans-retinoic acid at a concentration of 10 nM inhibited the growth of Capan 1 and Capan 2
cells by 40% relative to controls. 9-cis-Retinoic acid was less effective. Neither all-trans-retinoic acid nor 9-cis-
retinoic acid affected the growth of Hs766T cells. EB1089, if added alone to the cells, did not significantly
inhibit growth. However, the combination of 1 nM EB1089 with 10 nM all-trans-retinoic acid exerted a growth-
inhibitory effect of 90% in Capan 1 cells and of 70% in Capan 2 cells. Our data suggest that vitamin D
analogues together with retinoids inhibit the growth of human pancreatic cancer cells. However, in vivo studies
are necessary to examine the potential use of retinoids and vitamin D analogues on pancreatic cancer.
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Carcinoma of the pancreas is the fifth leading cause of death
from malignant disease in Western society. In the United
States incidence of pancreatic carcinoma has trebled in the
last 50 years (Kelly and Benjamin, 1995). Pancreatic
carcinoma is associated with an especially poor prognosis
(Jeekel, 1994). Neither radiotherapy nor chemotherapy
improve 5 year survival rates, which do not exceed 5%
(Wagener et al., 1994>. Therefore new therapeutic modalities
are essential for treating pancreatic carcinoma. There has
been increasing evidence that the steroid hormones retinoic
acid and vitamin D are naturally occurring agents controlling
cellular differentiation and proliferation both in normal and
malignant cells (Colston, 1993).
The biologically active form of vitamin D, 1,25-dihydroxy-
vitamin D3 [calcitriol-1,25(OH) D3] exerts effects unrelated to
calcium homeostasis such as inhibiting proliferation of cancer
cells (Cross et al., 1992). Receptors for vitamin D are present
in a variety of cancer cells, including pancreatic adenocarci-
noma (Reichel et al., 1989). However, a major drawback to
considering conventional vitamin D metabolites as therapeu-
tic agents is the production of hypercalcaemia at doses more
than a few micrograms per day (Reichel et al., 1989).
Recently a number of laboratories have developed synthetic
vitamin D analogues that inhibit cancer cell growth, but have
reduced calcaemic activity (Colston et al., 1992; Shabahang et
al., 1994). One compound, EB 1089, which is characterised
by a modified C17 side chain of the vitamin D molecule,
inhibits the growth of breast cancer cells in vitro and in vivo
(Colston et al., 1992).
Retinoids are natural and synthetic derivatives to vitamin
A (Bollag and Holdener, 1992). They elicit a large array of
biological responses during morphogenesis and differentiation
(Sporn and Roberts, 1983). Knowledge of the effects of these
compounds has led to the assumption that retinoids may act
as chemopreventive agents as well as inhibitors of tumour
growth (Bollag and Holdener, 1992). Retinoids have been
shown to depress tumour incidence and size in animal models
(Gudas, 1992). Studies with cancer cells demonstrate growth
inhibition induced by retinoids (Eliason et al., 1993; Peehl et
al., 1994).
Combining retinoids with cytokines such as interferon
leads to enhanced effects on tumours in vitro and in vivo
(Bollag and Peck, 1994). Additionally, recent investigations
have shown that retinoids together with vitamin D analogues
induce additive growth inhibition of myeloma cells,
leukaemic cells and breast cancer cells (Dore et al., 1993;
Lutzky et al., 1994; Bollag and Peck, 1994).
We set out to study the effects of the retinoids all-trans-
retinoic acid, 9-cis-retinoic acid and the vitamin D analogue
EB1089 on three human pancreatic cell lines, two were
derived from adenocarcinomas and one was derived from an
undifferentiated carcinoma.
Materials and methods
Cell culture
NRK fibroblasts and the human pancreatic cancer cell lines
Capan 1, Capan 2 and Hs766T were received from the
American Tissue Type Culture Collection (ATCC, Rockville,
MD, USA). Cell lines were cultivated in RPMI medium
(Gibco, UK) supplemented with 10% heat-inactivated fetal
bovine serum (FBS; Gibco, UK) and routinely tested for
mycoplasma contamination.
Retinoids and vitamin D
All-trans-retinoic acid, 9-cis-retinoic acid were a generous gift
from Hoffman La Roche (Basle, Switzerland). The vitamin D
analogue EB1089 was a generous gift from Leo pharmaceu-
tical (Copenhagen, Denmark).
Proliferation assays
Cells were plated into 24-well-plates (Costar) in RPMI
medium containing 10% FBS. Approximately 2000-5000
cells per well were added in 1 ml of medium. After 24 h
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retinoic acid or vitamin D analogues were added at various
concentrations. Three to six wells were run at each data
point. Cultures were allowed to grow in 5% carbon dioxide
at 37°C. L-Glutamine was added every 2 days. After 2, 4, 7
and 9 days cells were detached with trypsin EDTA (Gibco,
BRL) and their number was estimated using a Coulter cell
counter (Coulter). Viability had been determined by trypan
blue exclusion before cells were counted.
RNA isolation
Total cellular RNA was isolated by the phenol hot procedure
(Maniatis et al., 1989).
Vitamin D receptor (VDR)
Reverse transcription: 1 jug (7.5 ll) of total RNA was
denatured at 70°C for 10 min. Then RNA was transcribed
in RT-buffer (10 mM Tris pH 8.3, 50 mM potassium chloride,
1.5 mM magnesium chloride), 625 ,UM each dNTP, one unit of
RNasin (Boehringer), 10 mM dithiothreitol, 1 jug random
primer and five units of reverse transcriptase with a final total
volume of 30 pil. The reaction mixture was incubated for 1 h
at 37°C and for 10 min at 90°C. Polymerase chain reaction:
1.5 ,ul of cDNA product was amplified in 30 kul of 10 mM Tris
pH 8.3, 50 mM potassium chloride, 1.5 mM magnesium
chloride, 200 gM each dNTP, 0.5 /uM each primer and
1.25 U Taq polymerase (Boehringer). Thirty cycles were
performed, each consisting of 5 min at 95°C, 1 min at 58°C
and 2 min at 73°C. PCR products were loaded on an agarose
gel and stained with 1.5% ethidium bromide. The following
primers were used (Evans, 1988):
Sense VDR: 5'-CTCCAGTTCGTGTGAATGATGG
Antisense: 5'-TTGTAGTCTTGGTTGCCACAGG
RAR-ot
Reverse transcription and PCR were performed as described
by Pfeffer et al. (1995).
Reverse transcription A 100 ng aliquot of total RNA,
25 pmol of a short sequence-specific transcription primer
(5'-GGTTCAGGGTCAG, bp 1094-1082), 25 units of AMV
reverse transcriptase (Boehringer, Mannheim), 1 mM each
dNTP in a total volume of 20 ,u in PCR buffer (10 mM Tris-
HCL pH 8.3, 1.5 mM magnesium chloride, 50 mM potassium
chloride, 0.005% Tween 20, 0.005% NP40) were incubated
for 10 min at 25°C and for 45 min at 42°C. PCR was
performed in the same buffer on a mini cycler (MJ Research)
in 35 cycles consisting of 30 s at 94, 65, and 72°C each. The
following primers were used:
Sense: 5'-ACCCCCTCTTACCCCGCATCTACAAG (bp 460
-484)
Antisense: 5'-CCGTCTGAGAAAGTCATGGTGTC (bp 1092
-1070)
Products were separated by standard agarose gel electro-
phoresis and stained with ethidium bromide.
RAR-fl and RAR-y
Reverse transcription A 200 ng aliquot of total RNA, five
units reverse transcriptase with the following transcription
primers:
RAR-f,: 5'-GTCAAGGGTTCATGTCCTTC (bp 1593-1574)
RAR-y: 5'-CGGCGCCGGGCGTACAGC (bp 1302-1285)
Incubation was performed at 52°C for 30 min, at 99°C for
1 min and at 4°C for 5 min.
Seminested PCR was performed essentially as described by
Harant et al. (1993). In brief the first amplification was
performed in a 20 jl reaction mix that was composed of 2 pl
cDNA (equivalent to 500 ng of RNA), 2.5 ,ul of dNTP
(Sigma, St Louis, MO, USA) (5 nmol of each dATP, dCTP,
dGTP and dTTP), 2.5 !l each of 5' and 3' sequence primers
(10 pmol Iul
- each) and 5 pl of 10 x buffer (100 mM Tris-
HCl, pH 8.3, 500 mM potassium chloride, 15 mm magnesium
chloride, 0.1% gelatin) and brought with water to a final
volume of 20 ,ul. PCR was performed in a minicycler (MJ
Research) for 35 cycles. The incubation times per cycle were
40 s at 94°C, 30 s at 60°C, and 1 min at 72°C with an extra
5 min for the last cycle. The following primers were used:
RAR-f, sense: 5'-AGGAGACTTCGAAGCAAG (bp 822-839)
Antisense: 5' - GTCAAGGGTTCATGTCCTTC (bp 1593 -
1574)
RAR-y sense: 5'-GGAAGAAGGGTCACCTGA (bp 715-732)
Antisense: 5'-CGGCGCCGGGCGTACAGC (bp 1302- 1285)
The second amplification consisted in 25 cycles as
described above using the following degenerate primers:
RAR-f, (bp 921-939), y (bp 804-822)
A
TG C
Sense: 5'-CCTCGCTCTGCCAGCTGGG
Antisense primers are shown above
32-Microglobulin
Expression of the f32-microglobulin mRNA was used as an
internal control of the PCR reaction and reverse transcrip-
tion: in contrast to the RAR-PCRs (see above) samples were
taken after only 20 cycles, which is well before the time at
which the PCR reaction reaches its plateau (data not shown).
No signal without reverse transcription was obtained. The
following primers were used:
Sense: 5' - CAGCAAGGACTGGTCTTTCTATCTCTTGTA,
corresponding to bases 201 - 230 of the cDNA (Suggs et
al., 1981)
Antisense: 5' - GGAGCAACCTGCTCAGATACATCAAAA
CATGG,
corresponding to bases 539-510 of the cDNA.
Statistical analysis
For each data point mean and standard deviation were
calculated. Student's t-test was performed and a P-value of
<0.01 was considered statistically different.
Results
Anchorage-dependent growth assays
We studied the effects of all-trans-retinoic acid, 9-cis-retinoic
acid and the vitamin D analogue EB1089 on the anchorage-
independent growth of the human pancreatic adenocarcino-
ma cell lines Capan 1, Capan 2 and the undifferentiated
human pancreatic carcinoma cell line Hs766T. Cells were
incubated with concentrations of retinoids and EB1089
ranging from 1 pM to 1 ,UM. After 7 days of incubation cell
number was quantified and compared with that in medium
without added hormone. The anti-proliferative effects of all-
trans-retinoic acid and 9-cis-retinoic acid were dose
dependent (Figures 1 and 2). All-trans-retinioc acid at a
concentration of 10 nM inhibited the growth of the pancreatic
adenocarcinoma cell lines Capan 1 and Capan 2 by 40%
relative to untreated controls (Figure 1). 9-cis-retinoic acid at
the same concentration affected the growth by 25% as
compared with untreated controls (Figure 2). The growth of
the undifferentiated pancreatic carcinoma cell line Hs766Twas not affected by all-trans- or 9-cis-retinoic acid (data not
shown). The vitamin D analogue EB 1089 had a maximal
growth inhibitory effect of 25%, which was reached at a
concentration of 1 nM in all three cell lines (Figure 3, shown
for Capan 1 cells). Increasing concentrations of EB1089 did
not enhance this effect (Figure 3), however, EB1089
potentiated the effects of all-trans- and 9-cis-retinoic acid
(Figure 4). In the presence of 1 nM EB1089 all-trans-retinoic
acid, at a concentration of 10 nM, induced an inhibition of
90% of growth in Capan 1 cells and an inhibition of 70% of
growth in Capan 2 cells (Figure 4). 9-cis-Retinoic acid
(10 nM) in the presence of 1 nM EB1089 was not as effective
as all-trans-retinoic acid (Figure. 4). Vitamin D3 had the same
effects on growth as EB1089 (data not shown). All-trans-
retinoic acid up to a concentration of 1000 nM did not reduce
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the growth of non-tumorigenic NRK cells to a statistically
significant extent as compared with untreated controls
(Figure 5).
Expression of receptor mRNA
Total RNA was extracted from the three human pancreatic
cancer cell lines Capan 1, Capan 2 and Hs766T. RNA was
transcribed into cDNA and then amplified using gene-specific
primer pairs and polymerase chain reaction methodology.
For RAR-a a specific amplification product could be easily
detected corresponding in size to the product described by
Pfeffer et al. (1995) in MCF-7 human breast cancer cells
(Figure 6). No signal was obtained without reverse
transcription, indicating that mRNA was specifically
amplified. Because the first amplification revealed a very
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Figure 1 Effects of all-trans-retinoic acid on the anchorage-
dependent growth of Capan 1 (a) and Capan 2 (El) cells. Cells
were plated in triplicate in RPMI medium supplemented with
10% fetal bovine serum (FBS). After 24h compounds were
added. Fresh glutamine was added every 2 days. Cells were
counted after 7-9 days. Standard deviations were 5-10%.
Viability as determined by trypan blue exclusion was 90% in
untreated and treated cells.
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Figure 3 Effect of the vitamin D analogue EB1089 on the
anchorage-dependent growth of Capan 1 cells. Experiments were
conducted as described in Figure 1.
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Figure 2 Effects of 9-cis-retinoic acid on the anchorage-
dependent growth of Capan 1 (M) and Capan 2 (al) cells.
Experiments were conducted as described in Figure 1.
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Figure 4 Inhibitory effects of all-trans-retinoic acid and 9-cis
retinoic acid on the anchorage-dependent growth of Capan 1 (a)
and Capan 2 (El) cells in the presence of 1 nM EB1089.
Experiments were conducted as described in Figure 1.
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weak signal of RAR-f3 and RAR-y (data not shown), we
applied a seminested PCR as second amplification step for
detection of the mRNA of these two receptors. Using this
approach the three cell lines showed a strong signal of RAR-
y mRNA (Figure 6) corresponding to the specific product
described earlier in ovarian cancer cells (Harant et al., 1993).
In contrast, we found differential expression of RAR-fl
mRNA, which could be detected only in Hs766T cells,
matching the product described previously (Harant et al.,
1993) but neither in Capan 1 nor in Capan 2 cells (Figure 6).
Addition of 10 nM all-trans-retinoic acid induced RAR-fl
expression in Capan 1 (Figure 7) and Capan 2 cells (not
shown) but did not affect RAR-fl expression in Hs766T cells
(Figure 7). Expression of,2-microglobulin mRNA measured
after only 20 cycles of amplification was used as an internal
control that showed a similar intensity in all samples tested,
suggesting quantitative comparable PCR reactions (Figure 7).
For expression of vitamin D receptor mRNA a signal was
obtained in all cell lines using PCR after reverse transcription
(Figure 8), which was the size expected from the cDNA
sequence published earlier (Evans, 1988).
Discussion
Pancreatic cancer is poorly influenced by chemotherapy
(Jeekel, 1994), thus new therapeutic modalities are required
to improve long-term survival of patients (Wagener et al.,
1994). Since administration of retinoids has become an
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Figure 7 Effect of all-trans-retinoic acid on the expression of
RAR-a and ,B mRNA detected by PCR after reverse transcrip-
tion. Cells had been incubated with 10nM all-trans-retinoic acid
for 2 days (+ RA) as compared with untreated controls (-RA).
For comparison the expression of the /32-microglobulin mRNA
was determined in the same samples.
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Figure 5 Effects of all-trans-retinoic acid on non-tumorigenic
NRK cells. Experiments were conducted as described in Figure 1.
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Figure 6 Detection of retinoic acid receptor mRNA by PCR
after reverse transcription (+ RT) and without reverse transcrip-
tion (-RT). For detection of RAR-,B and y a seminested method
was applied.
Figure 8 Detection of vitamin D receptor (VDR) mRNA by
PCR after reverse transcription.
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established therapy of acute promyelocytic leukaemia,
members of the steroid super family may also become tools
for treating solid tumours (Reichel et al., 1989; Cross et al.,
1992; Bollag and Holdener, 1992; Gudas, 1992). In this paper
we report that synthetic retinoids together with the vitamin D
analogue EB1089 inhibit the growth of two cell lines derived
from human pancreatic adenocarcinomas. AII-trans-retinoic
acid has turned out to be a more potent growth inhibitor
than 9-cis-retinoic acid. The growth of one cell line derived
from an undifferentiated human pancreatic carcinoma was
not affected.
A number of studies have demonstrated growth-inhibitory
effects of retinoids and vitamin D in cancer. Eliason et al.
(1993) have shown anti-proliferative effects of the arotinoid
Ro 40-8757 on human breast, colon and cervical cancer cell
lines. Maximal effects are reached at a concentration of 1-
3 pM. Synthetic retinoids have therapeutic effects on breast
cancer (Teelman et al., 1993), ovarian cancer (Formelli and
Cleris, 1993) and prostate cancer (Pienta et al., 1993) in
animal models. However retinoids do not exert any effect on
growth of adenocarcinoma cells of the lung (Eliason et al.,
1993; Geradts et al., 1993). Retinoic acid receptors have been
demonstrated in ovarian cancer cell lines (Harant et al.,
1993), breast cancer cell lines (Roman et al., 1992), myeloma
cells and leukaemic cells (Lutzky et al., 1994; Dore et al.,
1993). There is no correlation between biological effects of
retinoids and degree of receptor expression (van-der Leede et
al., 1993; Lutzky et al., 1994), which is consistent with our
results. A lack of retinoic acid receptor subgroups such as
RAR-1 has been described in malignant tumours (Gudas,
1992; Xu et al., 1994; Swisshelm et al., 1994).
Lotan et al. (1995) have demonstrated in premalignant
oral lesions that the loss of expression of RAR-f can be
restored by treatment with isoretinoin. We have obtained
similar results. AII-trans-retinoic acid induces RAR-f
expression (Figure 7) and growth inhibition in Capan 1 and
Capan 2 cells (Figure 1), but affects neither RAR-f
expression (Figure 7) nor growth in Hs766T cells. RAR-f
expression in Hs766T cells does not depend on the presence
ofall-trans-retinoic acid (Figure 7). Although our data do not
allow a definite conclusion, they indicate that modulation of
receptor expression by the ligand rather than receptor
expression alone is associated with a biological effect. We
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